Abstract:Abstract Background Type 2 diabetes mellitus (T2DM) is a multifaceted disorder affecting epidermic proportion at global scope. Defective insulin secretion by pancreatic β-cells and the inability of insulin-sensitive tissues to respond appropriately to insulin are the primary causes of T2DM. Early detection of people at high risk of developing T2DM is of great importance as interventions such as dietary control and intentional weight loss can effectively improve the insulin sensitivity and prevent the disease incidence. However, circulating biomarkers that are indicative of early diabetic onset at asymptomatic stage have not been well described. Here, we aim to identify new serological markers indicating early asymptomatic onset of T2DM by MS-based metabolomic discovery. Methods Three independent cohorts were assembled for the study. The discovery cohort included sera from 25 patients with T2DM and 25 healthy controls. The validation cohort included sera from 15 patients with T2DM and 15 healthy controls. The testing cohort included sera from 111 patients with pre-diabetes and 89 healthy controls. Untargeted approach was used to characterize the serological metabolome by high performance liquid chromatography-high resolution mass spectrometry. Results The univariate analysis identified 11 metabolites that were significantly altered in patients with T2DM across discovery and validation cohorts. After evaluated by the testing cohort, 8 of 11 metabolites, such as hexose, N-acetyl-glucosamine, and alpha-ketobutyrate, remained statistically significant in patients with prediabetes as compared to healthy controls. The multivariate analysis based on 8 significant metabolites revealed distinct patterns of metabolic perturbation at the early onset of T2DM. To gain mechanistic insights into the disease pathophysiology, pathway enrichment and correlation network analyses were conducted to unveil the molecular crosstalk underlying the disturbed metabolic network in the pathogenesis of T2DM. Conclusion Our study not only identified serological biomarkers detecting early asymptomatic onset of T2DM but also provided additional insights into the disease pathophysiology.

The Potential of N-glycosylation Profiles As Biomarkers for Monitoring the Progression of Type II Diabetes Mellitus Towards Diabetic Kidney Disease

N-glycosylation profiling of Type 2 diabetes mellitus from baseline to follow-up: an observational study in a Ghanaian population

High Throughput Profiling of Whole Plasma N-glycans in Type II Diabetes Mellitus Patients and Healthy Individuals: A Perspective from a Ghanaian Population.

Targeted metabolomics as a tool for the diagnosis of kidney disease in Type II diabetes mellitus

Multi-block Data Integration Analysis for Identifying and Validating Targeted N-glycans As Biomarkers for Type II Diabetes Mellitus

Quantitative, Targeted Analysis of Gut Microbiota Derived Metabolites Provides Novel Biomarkers of Early Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients

Association of IgG N-glycomics with prevalent and incident type 2 diabetes mellitus from the paradigm of predictive, preventive, and personalized medicine standpoint

Utilization of N-glycosylation profiles as risk stratification biomarkers for suboptimal health status and metabolic syndrome in a Ghanaian population.

Biomarker Profiling with Targeted Metabolomic Analysis of Plasma and Urine Samples in Patients with Type 2 Diabetes Mellitus and Early Diabetic Kidney Disease

Metabolite Profiling of the Gut–Renal–Cerebral Axis Reveals a Particular Pattern in Early Diabetic Kidney Disease in T2DM Patients

Untargeted metabolomic profiling reveals molecular signatures associated with type 2 diabetes in Nigerians

Proteomic profiling reveals biomarkers and pathways in type 2 diabetes risk

Metabolomic Investigation of Blood and Urinary Amino Acids and Derivatives in Patients with Type 2 Diabetes Mellitus and Early Diabetic Kidney Disease

Systems biology and novel biomarkers for the early detection of diabetic kidney disease

The Potential Use of Targeted Proteomics and Metabolomics for the Identification and Monitoring of Diabetic Kidney Disease

Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: A review of the literature

Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients.

Biomarkers of diabetic nephropathy: A 2017 update

A-031 Global Discovery of Serological Metabolome Uncovers Unique Molecular Signature for Early Onset of Type 2 Diabetes Mellitus: A Retrospective Study in Chinese Population

Metabolic Profiles of Type 2 Diabetes and Their Association with Renal Complications.

Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study